Renin inhibitor VTP-27999 differs from aliskiren: Focus on their intracellular accumulation and the (pro)renin receptor

Journal of Hypertension

Volumn 32, Issue 6, 2014, Pages 1255-1263

  Lu, Xifeng ^a   Krop, Manne ^a   Batenburg, Wendy W ^a   Musterd Bhaggoe, Usha M ^a   Garrelds, Ingrid M ^a   Jan Danser, A H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cAMP; extracellular signal regulated kinase 1 2 phosphorylation; prorenin; renin; renin inhibitor; smallinterfering RNA; subcellular fractionation

Indexed keywords

ALISKIREN; CYCLIC AMP; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRORENIN; PRORENIN RECEPTOR; RENIN; RENIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VTP 27999; AMIDE; ANTIHYPERTENSIVE AGENT; CARBAMIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; FUMARIC ACID DERIVATIVE; METHYL (2-((3-CHLOROPHENYL)(1-((2-(METHYLAMINO)-3-(TETRAHYDRO-2H-PYRAN-3-YL)PROPYL)CARBAMOYL)PIPERIDIN-3-YL)METHOXY)ETHYL)CARBAMATE; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL LEVEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG LABELING; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE DELETION; GENE SILENCING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC 50; LYSOSOME; MAST CELL; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RENIN RELEASE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; IC50; METABOLISM; SMOOTH MUSCLE FIBER;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARBAMATES; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUMARATES; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LYSOSOMES; MAST CELLS; MITOCHONDRIA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PIPERIDINES; RATS; RECEPTORS, CELL SURFACE; RENIN; RNA, SMALL INTERFERING;

EID: 84900407010     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000167     Document Type: Article

References (24)

1. Jia L, Simpson RD, Yuan J, Xu Z, Zhao W, Cacatian S, et al. Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility. ACS Med Chem Lett 2011; 2:747-751.
2. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47:515-531.
3. Krop M, Lu X, Verdonk K, Schalekamp MADH, van Gool JM, McKeever BM, et al. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension 2013; 61:1075-1082.
4. Batenburg WW, Danser AHJ. (Pro)renin and its receptors: patho-physiological implications. Clin Sci (Lond) 2012; 123:121-133.
5. Krop M, Garrelds IM, de Bruin RJA, van Gool JM, Fisher ND, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
6. Lange S, Fraune C, Alenina N, Bader M, Danser AHJ, Frenay AR, et al. Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. J Hypertens 2013; 31:713-719.
7. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)-27 rats. Hypertension 2008; 52:130-136.
8. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51:682-688.
9. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN, Danser AHJ. Renin-and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)-renin receptor interaction actually occur? Hypertension 2011; 58:1111-1119.
10. Veerappan A, Reid AC, O'Connor N, Mora R, Brazin JA, Estephan R, et al. Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol 2012; 302:F192-F204.
11. Maibaum J, Stutz S, Goschke R, Rigollier P, Yamaguchi Y, Cumin F, et al. Structural modification of the P2' position of 2, 7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. J Med Chem 2007; 50:4832-4844.
12. van Kats JP, van Meegen JR, Verdouw PD, Duncker DJ, Schalekamp MA, Danser AHJ. Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens 2001; 19:583-589.
13. Batenburg WW, de Bruin RJA, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-1157.
14. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25:2441-2453.
15. Gross DM, Barajas L the large-scale isolation of renin-containing granules from rabbit renal cortex by zonal centrifugation. J Lab Clin Med 1975; 85:467-477.
16. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49:1157-1163.
17. Saris JJ, Derkx FH, de Bruin RJ, Dekkers DH, Lamers JM, Saxena PR, et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol 2001; 280:H1706-H1715.
18. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, et al the (pro)renin receptor/ATP6AP2 is essential for vacuolar H-ATPase assembly in murine cardiomyocytes. Circ Res 2010; 107:30-34.
19. Oshima Y, Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Bokuda K, et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011; 22:2203-2212.
20. Riediger F, Quack I, Qadri F, Hartleben B, Park J-K, Potthoff SA, et al. Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol 2011; 22:2193-2202.
21. Toei M, Saum R, Forgac M. Regulation and isoform function of the V-ATPases. Biochemistry 2010; 49:4715-4723.
22. Wagner CA, Finberg KE, Breton S, Marshansky V, Brown D, Geibel JP. Renal vacuolar H-ATPase. Physiol Rev 2004; 84:1263-1314.
23. Lu X, Garrelds IM, Wagner CA, Danser AHJ, Meima ME. (Pro)renin receptor is required for prorenin-dependent and-independent regulation of vacuolar H-ATPase activity in MDCK.C11 collecting duct cells. Am J Physiol Renal Physiol 2013; 305:F417-F425.
24. Liu G, Hitomi H, Hosomi N, Shibayama Y, Nakano D, Kiyomoto H, et al. Prorenin induces vascular smooth muscle cell proliferation and hypertrophy via epidermal growth factor receptor-mediated extracellular signal-regulated kinase and Akt activation pathway. J Hypertens 2011; 29:696-705.